Eli Lilly and Company (LLY)

Eli Lilly's stock price has been significantly impacted by several key events over the past six months. The company's stock has seen a substantial rally, increasing by 41% from August 2025 to the end of the year, largely driven by optimism surrounding its weight loss and diabetes treatments. As of January 9, 2026, the share price was $1,063.56, representing a 33.37% increase over the past year. Positive drivers include strong demand for its incretin portfolio, particularly Mounjaro and Zepbound, and the company's Q3 2025 revenue of $17.6 billion surpassed analyst expectations, leading to an increased full-year revenue guidance for 2025. Eli Lilly also announced a partnership with Nvidia, committing up to $1 billion over five years to accelerate AI-driven drug discovery, and made strategic acquisitions, including the purchase of Ventyx Biosciences for approximately $1.2 billion. On January 5, 2026, Novo Nordisk launched its "Wegovy Pill," the first oral weight-loss treatment in the U.S., which caused LLY shares to drop by approximately 3.6% due to increased competition in the oral GLP-1 market. Analysts generally maintain a "Buy" rating for Eli Lilly, with a consensus 12-month price target of $1,169.00.

While specific detailed information on the demand seasonality for all of Eli Lilly's products and services is not explicitly stated, the pharmaceutical industry, in general, can experience seasonality, particularly for products like vaccines. For Eli Lilly's major products, such as diabetes and weight-loss drugs, demand is likely to be relatively stable throughout the year rather than exhibiting strong seasonal fluctuations. Analysts expect double‑digit Q4 growth and Lilly has strong FY 2025/26 earnings expectations, suggesting some quarterly variations in financial performance or expectations.

Eli Lilly and Co. is an American multinational pharmaceutical company specializing in the discovery, development, manufacturing, and marketing of human healthcare products. The company focuses on therapeutic areas such as cardiometabolic health, oncology, immunology, and neuroscience, with key products including diabetes medications like Basaglar, Humalog, Jardiance, Trulicity, Mounjaro and Zepbound. Eli Lilly distributes its products through independent wholesale distributors to various entities, including wholesalers, pharmacy benefit managers, managed care organizations, hospitals, and retail pharmacies.

Eli Lilly maintains a significant global presence, with offices in 18 countries and products sold in approximately 125 countries. The company operates R&D, production, and distribution facilities across North America, South America, Europe, the Middle East, Africa, and Asia-Pacific. In Europe, Eli Lilly has over 9,000 employees and a considerable R&D and manufacturing presence in five countries, including Spain, France, Ireland, Italy, and Germany. The United States represents the largest portion of Eli Lilly's revenue by geographical region, accounting for 67.44% in fiscal year 2024, followed by Europe at 15.36%.

In the past year, Eli Lilly's brand reputation has faced scrutiny related to its marketing practices and legal challenges. In August 2025, the company received a severe reprimand in the Netherlands from the Code Committee of the Foundation for the Code of Pharmaceutical Advertising (CGR) for disseminating misleading and inaccurate information about its obesity drug Mounjaro. In June 2025, Eli Lilly filed lawsuits against several telehealth companies over the sale of compounded versions of its popular GLP-1 medications, Mounjaro and Zepbound.

Eli Lilly & Co. has a diverse ownership structure, with a significant portion held by institutional investors. Approximately 80.69% of the company's stock is owned by institutional shareholders, 10.51% by Eli Lilly & Co. insiders, and 8.79% by retail investors. Major institutional owners include Lilly Endowment Inc., Vanguard Group Inc., BlackRock, Inc., PNC Financial Services Group, Inc., State Street Corp, Capital Research Global Investors, Fmr Llc, and Geode Capital Management, Llc.